A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
AgeNot listed
SponsorAkeso
About this trial
This is an observational and non-interventional clinical study that only collects long-term follow-up data of the subjects. As the world's first approved PD-1/CTLA-4 bispecific antibody for marketing, Cadonilimab may confer long-term survival benefits.
Eligibility criteria
This trial does not accept healthy volunteersQualifiers
Ability to understand and voluntarily sign a written informed consent form (ICF), which must be signed before the specified study procedures required for the study are performed.
Subjects have received prior systemic therapy in sponsor-initiated clinical trials of cadonilimab (AK104), and this extension study is conducted after the completion of the original trial.
Agree to proceed with the extended follow-up procedures.
This is an observational and non-interventional clinical study, in which subjects are allowed to participate in other clinical studies at the same time.
Disqualifiers
None
Trial population
Subjects are enrolled from participants who previously took part in the sponsor-initiated clinical trials of cadonilimab (AK104).
Trial design
Design model
Cohort
Time perspective
Prospective
Treatments tested in this trial
Not listed
Trial groups
No trial groups listed
Trial outcomes
Primary outcomes
1
Overall Survival (OS)
OS is defined as the time from randomization to death due to any cause.
Time frame
Up to approximately 5 years Source ClinicalTrials.gov